Immutep GmbH

General information
Immutep GmbH
Deutscher Platz 5a
04103 Leipzig, Saxony
Germany

Contact person: Christian Rudolf, Office & IT Manager
Company main phone: +49 (341) 23100372
Website:  https://www.immutep.com/
Source of foundation:Subsidiary
Name of foundation source:Prima BioMed Ltd, Australia
Corporate description / mission:
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. The company's products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer.
State of ownership: Subsidiary
Headquarters: No
Remarks on ownership / listings
Headquartered at Immutep Limited, Australia.

Formerly Prima BioMed.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Immunotherapy
  • Proteins
  • Other
Primary therapeutic areas:
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
Business model:
  • Manufacturer
  • R&D
  • Subsidiary
Customer segments:
  • Other
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Description of products:
IMP701, a blocking anti-LAG-3 antibody for cancer
IMP761, an agonist antibody of LAG-3, etc.
Technology used:
LAG-3 Technology
© 2023 Biotechgate by Venture Valuation
X